Drug Profile
HPP 854
Alternative Names: HPP854; TTP-854Latest Information Update: 31 Mar 2016
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Developer High Point Pharmaceuticals
- Class Small molecules
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 10 Sep 2014 No development reported - Phase-I for Alzheimer's disease in USA (PO)
- 31 Aug 2012 High Point Pharmaceuticals terminates phase I trial in Alzheimer's disease in USA (NCT01482013)
- 01 Oct 2011 High Point Pharmaceuticals initiates enrolment in a phase I trial in Alzheimer's disease in USA (NCT01482013)